| General information | |
| ACovPid: | ACoVP100215 |
| Trivial Name: | RBD-11b |
| Amino Acids Sequence: | YKYRYL |
| Length: | 6 |
| C-Terminal Modification: | None |
| N-Terminal Modification: | None |
| Chemical Modification: | None |
| Peptide Source: | Severe acute respiratory syndrome coronavirus (SARS-CoV) : 694009 |
| Source Description: | From the receptor-binding domain (RBD) of the spike protein of SARS-CoV |
| Against Virus: | Severe acute respiratory syndrome coronavirus (SARS-CoV) : 694009 |
| Inhibition Value Type: | IC90 |
| Inhibitory Effect: | 1400 |
| Inhibitory Unit: | µM |
| Target Domain Name: | |
| Assay: | Cell-cell fusion |
| Assay Description: | VeroE6 cells were infected with the SARS-CoV isolate Frankfurt. As described previously, growth of the virus in Vero cells is not associated with a cytopathic effect. Cells were infected with a virus titer of 0.01 MOI. The inoculum was removed after 1 h and replaced with fresh medium complemented with different concentrations of peptide RBD-11b in a one-time dose. Two days post infection virus RNA concentration in the supernatant was measured by real-time PCR (cf. Fig. 4 ). There was no evidence for toxicity of the compound in the concentration range tested with MTT cell proliferation assay on subconfluent cells. After two days a one-time dose of the peptide RBD-11b (YKYRYL, 10.5 mM) reduced the virus RNA level compared to the untreated control by a factor of 10. Further, the inhibition of virus proliferation by the peptide is concentration dependent. After two days, relative to an untreated control virus RNA is reduced by a factor of 600 at a 14 mM concentration of the peptide. |
| Anti-CoV activity in vivo: | |
| Reference: | 22265858 |
| Comment: | |
| 3D structure: | |
| Structure Experiment Verified: | NO |
| Similar Peptides: | ACoVP100514 |